Protocol  1.  Project  Title:  A  pi[INVESTIGATOR_823903]  (Not  Impossible  Vibrohealth)  on  motor  control  and  symptoms  in  patients  with  movement  disorders    2.  Investigators:  Christopher  W.  Hess,  MD  (PI)  Wei  Hu,  MD  (Co-­I)  Michael  S.  Okun,  MD  (Co-­I)    3.  Abstract:  Non-­invasive  vibrotactile  stimulation  (VTS)  of  the  skin  has  long  been  reported  anecdotally  to  potentially  improve  motor  control  and  reduce  the  motor  symptoms  of  patients  with  movement  disorders  including  Parkinson’s  disease.  Though  few  rigorously  controlled  clinical  trials  have  been  performed  on  the  effects  of  VTS,  devices  that  provide  VTS  have  received  significant  media  attention  as  potential  non-­medical  interventions  for  movement  disorders.  In  this  study,  we  will  test  the  effect  of  VTS  applied  non-­invasively  to  patients  with  movement  disorders  to  determine  if  there  are  any  beneficial  effects  of  VTS  on  common  tasks  of  motor  control  and/or  abnormal  motor  symptoms  in  patients  with  PD,  essential  tremor  (ET),  and  dystonia.      4.    Background:  Movement  disorders  can  be  defined  as  neurologic  syndromes  in  which  there  is  either  an  excess  or  paucity  of  voluntary  and/or  automatic  movements  that  is  not  due  to  weakness  or  spasticity.  A  prototypi[INVESTIGATOR_823904]’s  disease  (PD),  a  chronic  progressive  neurodegenerative  disorder  characterized  by  [CONTACT_450293],  bradykinesia,  gait  and/or  postural  instability,  and  resting  tremor.  1  The  classical  PD  tremor  has  a  dominant  frequency  of  3–6Hz  and  is  most  often  present  at  rest  in  the  upper  extremities  of  the  affected  subjects.  Other  movement  disorders  include  essential  tremor  (ET,  in  which  tremor  is  
predominantly  present  with  action)  and  dystonia  (in  which  tremor  is  associated  with  a  syndrome  of  abnormal  muscle  contractions  resulting  in  involuntary  movements  and  postures).  Although  medical  and  surgical  therapi[INVESTIGATOR_823905],  current  treatment  options  can  produce  significant  side  effects  and  often  provide  incomplete  benefit  for  the  motor  symptoms  of  these  diseases.  Therefore,  continued  investigation  of  new  potential  treatment  options  is  an  important  priority.    The  application  of  external  non-­invasive  vibrotactile  stimulation  (VTS)  of  the  skin  as  a  therapeutic  intervention  for  movement  disorders  has  been  of  interest  since  the  19th  century,  when  Jean-­Martin  Charcot  anecdotally  observed  a  relief  of  symptoms  following  the  use  of  a  vibrating  chair  in  patients  with  PD.  [ADDRESS_1142436]  been  inconsistent.  3-­[ADDRESS_1142437]  one  wearable  health-­related  technology,  and  wearable  devices  intended  to  track  the  symptoms  of  PD  10  are  already  in  clinical  use.  Wearable  devices  that  provide  VTS  (such  as  the  as  the  Vibrohealth  system  recently  developed  by  [CONTACT_823920],  https://www.youtube.com/watch?v=G7T53xN1IqI)  have  received  significant  attention  in  the  lay  press  and  within  patient  support  groups.  As  more  and  more  wearable  devices  (which  may  be  marketed  directly  to  patients)  are  developed,  it  will  be  critically  important  for  academic  clinical  researchers  to  participate  in  testing  the  efficacy  of  these  devices  in  rigorous  clinical  trials.  This  need  for  independent  study  has  been  recognized  by  [CONTACT_823921]’s  Foundation  (PF),  which  has  selected  the  University  of  [LOCATION_012]  as  a  research  site  tasked  with  determining  the  optimal  device  settings  and  testing  the  Not  Impossible  Vibrohealth  system  as  an  adjunctive  therapy  for  movement  disorders.  We  will  accomplish  this  through  the  following  specific  aims.    5.    Specific  Aims:  
Specific  Aim.  Evaluate  the  feasibility,  reliability,  and  clinical  effects  of  VTS  on  basic  tasks  of  motor  control  and  on  the  motor  symptoms  of  patients  with  movement  disorders.    Hypothesis:  VTS  will  produce  beneficial  effects  on  basic  tasks  of  motor  control  and  abnormal  motor  symptoms  in  patients  with  movement  disorders.  VTS  Settings  will  include  continuous  stimulation  between  60-­120  Hz,  intermittent  stimulation  at  ½  baseline  step  frequency  during  walking,  and  sham  stimulation  (2  seconds  of  30  Hz  stimulation  only  at  stimulation  onset).    6.  Research  Plan:  6.1    Design  Overview:  This  cross-­sectional  pi[INVESTIGATOR_823906]-­medication  state.  After  informed  consent,  screening,  and  recruitment,  the  effects  of  VTS  will  be  evaluated  on  basic  tests  of  motor  control  and  common  movement  disorders  symptoms.      6.2    Participants:  We  will  recruit  30  patients  with  PD  who  are  between  the  ages  of  18-­80  years  old  and  independently  living  in  the  community.  Will  additionally  recruit  up  to  5  patients  with  ET  and  up  to  5  patients  with  dystonia.  To  account  for  screening  failures  or  patients  who  cannot  tolerate  the  sensory  stimulation,  we  anticipate  screening  and  consenting  ~50  individuals.    6.3    Recruitment:  Recruitment  will  occur  exclusively  through  the  UF  movement  disorders  program  at  the  Fixel  Institute  for  Neurological  Diseases  at  UF  Health.  We  expect  to  recruit  patients  prior  to  and  during  routine  scheduled  clinic  visits  with  e-­consenting  (electronic  informed  consent).  
  6.4    Inclusion/Exclusion  Criteria:  6.4a.  Inclusion  criteria:  •  Age  18-­80  and  able  to  provide  informed  consent.  •  Have  a  diagnosis  of  Parkinson’s  disease,  essential  tremor,  or  cervical  dystonia  made  by  a  movement  disorders  specialist.  •  Medically  optimized  without  planned  medication  changes  for  the  duration  of  the  study.    •  For  patients  with  ET,  they  will  have  a  score  of  at  least  2  on  items  5  and  6  of  the  Fahn-­‐‑Tolosa-­‐‑Marin  (FTM)  Tremor  Rating  Scale.    •  For  patients  with  dystonia,  they  will  have  abnormal  dystonic  postures  of  the  head  and  not  isolated  head  tremor  6.4b.  Exclusion  criteria:      •  The  presence  of  additional  neurologic  diseases,  that  might  confound  testing  or  the  coexistence  of  PD  and  ET  together  (action  tremor  that  was  present  prior  to  the  development  of  parkinsonism).  •  Symptoms  of  peripheral  neuropathy  at  the  wrist  (reduced  vibratory,  pi[INVESTIGATOR_29107],  or  temperature  sensation)    •  Montreal  cognitive  assessment  (MoCA)  score  <  20  or  previously  documented  dementia  •  Unable  to  walk  without  a  walking  aid  (e.g.  cane,  stick,  walker)  
6.[ADDRESS_1142438]  charger  (Figure  1).  The  devices  are  paired  with  a  cell  phone  application  (to  be  used  solely  by  [CONTACT_823922])  that  adjusts  the  parameters  of  vibratory  stimulation  during  research  visits  (Figure  2).      The  device  consists  of  an  actuator/sensor  that,  when  placed  against  the  surface  of  the  skin,  produces  a  vibrotactile  sensation  (vibration)  through  rapid  lateral  (side  to  side)  motion.  The  intensity  of  the  vibration  produced  by  [CONTACT_823923].  The  sensor  in  the  device  is  a  tri-­axial  accelerometer  and  gyroscope  that  measures  position  using  the  same  technology  as  smartphones.    A  previous  version  of  the  Vibrohealth  device  was  evaluated  in  2017-­2018  on  52  patients  with  PD  and  resting  tremor  at  the  Mount  Sinai  Hospi[INVESTIGATOR_823907]  a  study  funded  by  [CONTACT_823924]  (Not  Impossible).  The  Vibrohealth  device  was  deemed  a  nonsignificant  risk  device  and  was  approved  by  [CONTACT_823925]  (IRB  #17-­[ZIP_CODE]).  There  were  no  adverse  events  in  any  subjects  receiving  VTS.  However,  the  stimulation  setting  intended  to  serve  as  a  sham  control  setting  (low  amplitude  continuous  vibration)  appeared  to  reduce  resting  tremor  in  approximately  60%  of  patients,  suggesting  that  the  vibration  settings  used  in  the  protocol  were  inadequately  investigated  prior  to  study  design.  Though  this  study  is  being  prepared  for  publication  by  [CONTACT_823926][INVESTIGATOR_823908]  a  safety  and  feasibility  study,  the  Parkinson  

Foundation  has  decided  to  fund  further  pi[INVESTIGATOR_823909].    We  have  tested  the  Vibrohealth  device  on  7  patients  during  our  initial  pi[INVESTIGATOR_823910].      6.6    Screening/Baseline  Interview  and  Measures:  Recruitment  will  be  conducted  at  the  UF  Health  Fixel  Institute  for  Neurological  Diseases  via  pre-­review  of  outpatient  appointments,  review  of  the  IRB  approved  movement  disorders  database,  and  during  standard  of  care  (SOC)  visits.  Clinic  providers  involved  with  the  research  study  who  provide  clinical  care/intervention  for  treatment  may  also  discuss  the  protocol/research  with  their  patient.  If  participants  are  identified  through  pre-­review  of  outpatient  records/lists/appointments,  providers  associated  with  clinical  care  for  the  subject  will  be  notified  of  the  subject’s  potential  availability.  No  other  information  will  be  collected  during  the  pre-­screening  process.  The  provider  will  then  mention  the  study  to  the  patient,  if  appropriate.  When  interested,  subjects  will  either  contact  [CONTACT_823927].    Study  personnel  will  tell  the  potential  participants  about  the  study.  The  study  personnel  will  consist  of  the  investigators  (UF  faculty),  staff  study  coordinators,  and  clinical  movement  disorders  fellows.  All  study  coordinators  will  be  appropriately  trained  to  meet  HIPPA  and  IRB  requirements.  The  pre-­screening  of  records  will  only  be  carried  out  by  [CONTACT_823928].    Patients  will  also  be  identified  using  the  Fixel  Institute  for  Neurological  Diseases  patient  database  (Quantifying  Deficits  in  Patients  with  Movement  Disorders).  Patients  who  have  provided  informed  consent  to  have  their  medical  information  stored  in  the  database  and  have  indicated  that  they  would  like  to  be  contact[CONTACT_823929]  (IRB201501166).  Potential  participants  will  be  identified  using  database  queries  including  diagnosis,  age,  location,  most  recent  UPDRS,  and  most  recent  clinical  visit.  These  identified  potential  participants  will  then  be  contact[CONTACT_823930].    
Once  a  potential  participant’s  interest  in  participating  in  the  study  is  established,  the  study  personnel  will  read  from  an  approved  telephone  script  to  provide  details  about  the  study  and  the  inclusion  and  exclusion  criteria.  If  potential  participants  are  still  interested  and  are  eligible  to  participate  in  the  study,  they  will  then  be  scheduled  for  an  e-­consenting  appointment.      6.7    Duration  of  Study  and  Overview  of  Procedures  and  Protocol:  Testing  will  occur  over  the  course  of  a  single  day  at  the  Fixel  Institute  for  Neurological  Diseases.  Similar  to  new  patient  clinical  evaluations,  subjects  will  be  instructed  to  withhold  any  PD,  ET,  or  dystonia  medications  for  [ADDRESS_1142439]  up  to  4  hours  and  will  include  a  variety  of  motor  tasks  and  clinical  tests  (described  in  detail  below)  both  on  and  off  VTS.  For  Parkinson’s  disease  and  essential  tremor  patients,  the  devices  will  be  worn  on  the  wrist  and/or  ankles.  For  patients  with  dystonia,  the  devices  will  be  adhered  to  the  skin  of  the  neck  using  medical  grade  double  sided  tape  and  a  latex  medical  wrap.  Patients  with  PD  will  undergo  a  more  comprehensive  testing  evaluation,  while  patients  with  ET  or  dystonia  will  undergo  a  brief,  more  focused  evaluation.  Subject  responses  will  not  be  compared  across  diseases  given  the  preliminary  nature  of  the  research  and  analysis.    Outcomes  to  be  measures  are  described  below  in  the  order  that  they  will  be  tested  for  each  individual  subject  group  (PD,  ET,  dystonia).      Baseline  testing:  MDS-­UPDRS:  Select  measures  from  the  motor  section  of  the  Movement  Disorders  Society  Unified  Parkinson’s  Disease  Rating  Scale  (MDS-­UPDRs).  11  The  MDS-­UPDRS  is  a  revision  of  the  Unified  Parkinson’s  Disease  Rating  Scale  (UPDRS)  originally  developed  in  the  1980s.  The  scale  is  used  in  the  clinic  as  well  as  in  research  to  measure  PD  symptom  severity.  Individual  measures  are  rated  as  0  (normal)  to  4  (severe).    
Montreal  Cognitive  Assessment  (MoCA):  The  MoCA  is  a  cognitive  screening  test  designed  to  assist  Health  Professionals  in  the  detection  of  mild  cognitive  impairment  and  dementia.  It  will  be  used  to  exclude  patients  with  cognitive  impairment  significant  enough  to  confound  the  research  variables  of  interest.    6.7a:  Outcomes  to  be  measured  in  subjects  with  PD:    Quantitative  Tremor  Assessment:  An  external  accelerometer  (Delsys  Trigno;;  https://delsys.com/trigno/)  will  be  adhered  to  the  skin  of  the  dorsum  of  the  hand  and  will  be  used  to  quantify  displacement  of  the  hand  due  to  tremor  in  the  settings  listed  below.  Delsys  Trigno  sensors  have  been  used  in  multiple  prior  UF  IRB  approved  studies  and  is  FDA  and  CE  registered  with  FCC  ID,  and  is  certified  IEC601-­1  (General  Requirements  for  Medical  Devices)  and  IEC601-­1-­2  (electromagnetic  compatibility  requirements  for  Medical  Devices)  with  a  UL  recognized  Internal  Battery.    -­  1.  Sitting  at  rest  -­  2.  Sitting  with  both  arms  outstretched  -­  3.  Sitting  at  rest  while  performing  a  distracting  cognitive  task  (reciting  the  months  of  the  year  backwards)  -­  4.  Transition  from  rest  to  posture  (arms  held  directly  in  front  of  patient)  for  10  seconds    Kinesia  One  accelerometer:  The  following  select  measures  of  MDS-­UPDRS  Part  III:  Motor  Examination  will  be  repeated  before  and  during  VTS:    3.4  Finger  tappi[INVESTIGATOR_007]  3.5  Hand  movements  3.6  Rapid  alternating  movements  (pronation-­supi[INVESTIGATOR_823911])    These  measures  will  be  quantified  using  the  Kinesia  one  accelerometer  system  (http://glneurotech.com/kinesia/products/kinesia-­one/),  which  uses  a  propriety  algorithm  
to  calculate  a  severity  score  on  a  0-­4  scale  that  has  been  shown  to  highly  correlate  with  clinician  ratings.  The  Kinesia  one  system  has  been  used  in  multiple  prior  UF  IRB  approved  studies  and  is  FDA  cleared  to  market  and  CE  marked.  The  device  is  placed  on  the  index  finger  during  testing  and  senses  movement.      Reaction  time  task:  Subjects  will  look  at  a  central  fixation  symbol  on  computer  screen  and  press  a  computer  keyboard/mouse  button  when  the  GO  signal  appears.  The  time  between  the  onset  of  the  fixation  cross  and  the  green  GO  signal  will  vary  so  that  the  onset  of  the  GO  signal  will  not  be  predictable.  The  time  between  appearance  of  the  GO  signal  and  recorded  keyboard  response  will  be  recorded  as  reaction  time.  13    Functional  Dexterity  Task  (FDT):  The  FDT  is  a  pegboard  assessment  of  manual  dexterity.  It  is  a  square  pegboard  with  [ADDRESS_1142440],  as  quickly  as  possible,  using  one  hand  at  a  time.  A  5-­s  penalty  is  added  every  time  the  subject  supi[INVESTIGATOR_823912],  while  a  10-­s  penalty  is  added  if  the  subject  drops  a  peg.  Two  scores  are  obtained:  the  net  time  (in  seconds)  quantifies  the  speed  of  the  hand  dexterity;;  the  total  score  (time  plus  penalties)  quantifies  the  quality  of  the  performance.  The  test  ends  when  both  hands  have  completed  the  task  and  the  total  score  for  each  hand  determines  the  functional  level.    Timed-­up-­and-­go  (TUG)  gait  task:  Subjects  are  asked  to  stand  up  from  a  chair,  walk  [ADDRESS_1142441]  which  will  be  scored  by  a  blinded  rater  for  number  of  freezing  epi[INVESTIGATOR_823913].  The  TUG  task  will  be  performed  on  the  instrumented  GAITRite  mat  (https://www.gaitrite.com/)  which  is  located  in  the  clinic  and  is  routinely  used  for  clinical  care.  The  GAITRite  mat  measures  and  records  spatiotemporal  components  of  gait  including  stride  length,  regularity,  cadence,  left-­sided  step  length,  
right-­sided  step  length,  velocity,  and  an  overall  functional  ambulation  score.  The  GAITRite  mat  is  FDA  registered,  CE  Certified  and  ISO  standard  compliant.  Clinical  Global  Impression  (CGI-­I)  Scale:  The  Clinical  Global  Impression-­Improvement  (CGI)  scale  was  developed  for  use  in  NIMH-­sponsored  clinical  trials.  14  It  is  a  7-­point  scale  that  requires  the  clinician  to  assess  how  much  a  specific  symptom  has  improved  or  worsened  relative  to  a  baseline  state  prior  to  an  intervention.    6.7b:  Outcomes  to  be  measured  in  subjects  with  ET:  FTM-­TRS:  Select  measures  from  the  Fahn-­Tolosa-­Marin  Tremor  Rating  Scale  (FTM-­TRS).  15  The  FTM-­TRS  is  the  most  commonly  used  rating  scale  in  clinical  trials  of  essential  tremor.  It  rates  tremor  on  a  scale  of  0  (no  tremor)  to  4  (severe).  Select  measures  of  FTM-­TRS  to  be  tested  are  as  follows:    5.  right  upper  extremity  tremor  (rest,  posture,  action):  6.  left  upper  extremity  tremor  (rest,  posture,  action):  10.  Handwriting  22.  Spi[INVESTIGATOR_823914]  (CGI-­I)  Scale:  as  described  above  in  PD  section.    6.7c:  Outcomes  to  be  measured  in  subjects  with  dystonia:  TWSTRS:  Select  measures  from  the  motor  section  of  the  Toronto  Western  Spasmodic  Torticollis  Rating  Scale  (TWSTRS).  [ADDRESS_1142442]  measures  of  the  TWSTRS  section  A  to  be  tested  are  as  follows:  1.  Rotation  2.  Laterocolis  
3.  Anterocollis/retrocollis  4.  Lateral  shift  5.  Sagittal  shift    Clinical  Global  Impression  (CGI-­I)  Scale:  as  described  above  in  PD  section.    7.    Outcome  and  Statistical  Approaches:  For  essential  tremor  and  dystonia,  the  aims  of  this  unblinded  pi[INVESTIGATOR_823915],  statistical  analysis  will  be  limited  to  basic  measures  of  central  tendency.  We  will  compare  scores  and  values  on  the  individual  outcome  measures  listed  above  both  on  and  off  VTS,  and  within  disease  group  means  for  each  measure  will  be  used  to  help  guide  the  choice  of  settings  to  be  tested  in  future  studies.  This  pi[INVESTIGATOR_823916],  or  dystonia.    For  Parkinson’s  disease,  we  expect  to  have  data  sufficient  to  justify  exploratory  statistical  analysis.  We  have  estimated  that  the  number  of  patients  included  will  allow  for  statistical  analysis  of  patient’s  task  performance  before  and  during  VTS.  This  was  based  on  a  medium  effect  size  (cohen’s  d  =  0.50)  for  the  comparison  of  tremor  power  during  VTS  versus  baseline.  With  an  alpha  of  0.05  and  power  of  0.80,  the  required  sample  size  is  27  (based  on  a  one-­sided  paired  sample  t-­test).  Thus,  by  [CONTACT_30224]  [ADDRESS_1142443]-­hoc  analyses  will  be  corrected  for  multiple  comparisons  using  Bonferroni  correction.      8.    Methodological  Limitations  and  Potential  Challenges:    Potential  challenges  that  may  occur  during  the  study  include  subject  discontinuation  prior  to  completion  of  data  collection  due  to  boredom  or  irritation  of  the  skin  from  vibration.  Partial  collected  data  will  still  be  useful  in  helpi[INVESTIGATOR_823917],  ET,  or  dystonia.        9.  Data  Management  Plan:  All  data  (including  videos)  collected  from  subjects  will  be  stored  in  encrypted  computer  files  with  secure  passwords.  All  data  entered  into  such  electronic  storage  files  will  be  assigned  subject  ID  numbers  that  are  de-­identified  to  ensure  that  all  information  is  protected.  Data  will  be  kept  in  a  password  protected  encrypted  database  which  can  only  be  accessed  by  [CONTACT_823931].    All  data  and  assessments  will  be  under  the  direction  of  the  Co-­PI’s  who  will  supervise  research  coordinators  and  assistants.    Subject  numbers  will  be  assigned  consecutively  as  follows:      Subjects  with  PD:  PD1,  PD2,  etc.  to  PD30  Subjects  with  ET:  ET1,  ET2,  etc.  to  ET5  Subjects  with  dystonia:  DYT1,  DTY2,  DYT3,  etc.  to  DYT5    De-­identified  data  may  be  compared  with  data  collected  by  [CONTACT_823932]’s  Foundation.  No  data  that  includes  any  HIPAA  identifiers  will  be  available  to  Not  Impossible  or  to  other  research  groups  or  anyone  outside  of  the  study  researchers  and  coordinators  noted  in  this  protocol.      10.    Possible  Discomforts  and  Risks:  In  general,  the  risks  are  minimal  for  individuals  who  participate  in  this  study.  As  the  intensity  of  the  vibration  produced  by  [CONTACT_823933],  the  incidence  and  severity  of  any  adverse  effects  is  expected  to  be  limited,  and  no  adverse  events  occurred  in  a  previous  trial  using  the  Vibrohealth  device  in  over  [ADDRESS_1142444]  the  VTS  stimulation  could  be  annoying  or  unpleasant,  and  there  is  the  possibility  of  minor  skin  irritation  at  the  site  where  the  wearable  devices  are  placed.  
Second,  subjects  will  be  asked  to  come  to  testing  sessions  OFF  medications  (as  is  done  during  standard-­of-­care  initial  clinic  visits)  in  order  to  reduce  confounding  effects  of  medications,  which  could  be  temporarily  uncomfortable.  Third,  patients  may  also  find  the  tasks  and  scales  tedious  or  boring.  To  minimize  fatigue  associated  with  completion  of  screening  and  tasks,  subjects  will  be  allowed  to  take  frequent  breaks  to  rest  as  needed.  Patients  will  have  the  option  of  discontinuing  testing  at  any  time,  and  data  that  is  partially  collected  may  still  be  useful  given  the  preliminary  nature  of  the  study.  Though  unlikely,  it  is  possible  skin  irritation  might  persist  outside  of  the  testing  period.  Should  this  occur,  the  patient  would  be  instructed  to  seek  routine  medical  care.  It  is  also  possible  that  there  are  unknown  risks  for  participating  in  this  study.    11.  Possible  Benefits:  It  is  possible  that  VTS  might  temporarily  improve  tasks  of  motor  control  or  reduce  movement  disorders  symptoms.  Subjects  will  also  have  the  satisfaction  of  knowing  that  they  are  helpi[INVESTIGATOR_823918]  a  controlled  unbiased  setting.    12.  Conflict  of  Interest:  The  study  investigators  have  no  conflicts  of  interest.                      
        References  1.  Hess  CW,  Okun  MS.  Diagnosing  Parkinson  Disease.  Continuum  (Minneap  Minn).  2016;;22(4  Movement  Disorders):1047-­1063.  2.  Charcot   JM.   Vibratory   therapeutics.-­-­The   application   of   rapid   and   continuous  vibrations  to  the  treatment  of  certain  diseases  of  the  nervous  system.  1892.  J  Nerv  Ment  Dis.  2011;;199(11):821-­827.  3.  Gassner  H,  Janzen  A,  Schwirtz  A,  Jansen  P.  Random  Whole  Body  Vibration  over  5  Weeks  Leads  to  Effects  Similar  to  Placebo:  A  Controlled  Study  in  Parkinson's  Disease.  Parkinsons  Dis.  2014;;2014:386495.  4.  Haas   CT,   Turbanski   S,   Kessler   K,   Schmidtbleicher   D.   The   effects   of   random  whole-­body-­vibration   on   motor   symptoms   in   Parkinson's   disease.  NeuroRehabilitation.  2006;;21(1):29-­36.  5.  Jobges   EM,   Elek   J,   Rollnik   JD,   Dengler   R,   Wolf   W.   Vibratory   proprioceptive  stimulation   affects   Parkinsonian   tremor.  Parkinsonism   Relat   Disord.  2002;;8(3):171-­176.  6.  Kapur   SS,   Stebbins   GT,   Goetz   CG.   Vibration   therapy   for   Parkinson's   disease:  Charcot's  studies  revisited.  J  Parkinsons  Dis.  2012;;2(1):23-­27.  7.  King  LK,  Almeida  QJ,  Ahonen  H.  Short-­term  effects  of  vibration  therapy  on  motor  impairments  in  Parkinson's  disease.  NeuroRehabilitation.  2009;;25(4):297-­306.  8.  Grunewald  RA,  Yoneda  Y,  Shipman  JM,  Sagar  HJ.  Idiopathic  focal  dystonia:  a  disorder  of  muscle  spi[INVESTIGATOR_823919]?  Brain.  1997;;120  (  Pt  12):2179-­2185.  9.  Cussons   PD,   Matthews   PB,   Muir   RB.   Enhancement   by   [CONTACT_823934].  J   Physiol.  1980;;302:443-­461.  10.  Joshi  R,  Bronstein  JM,  Keener  A,  et  al.  PKG  Movement  Recording  System  Use  Shows   Promise   in   Routine   Clinical   Care   of   Patients   With   Parkinson's   Disease.  Front  Neurol.  2019;;10:1027.  11.  Goetz  CG,  Tilley  BC,  Shaftman  SR,  et  al.  Movement  Disorder  Society-­sponsored  revision   of   the   Unified   Parkinson's   Disease   Rating   Scale   (MDS-­UPDRS):   scale  presentation  and  clinimetric  testing  results.  Mov  Disord.  2008;;23(15):2129-­2170.  12.  Zach   H,   Dirkx   MF,   Roth   D,   Pasman   JW,   Bloem   BR,   Helmich   RC.   Dopamine-­responsive   and   dopamine-­resistant   resting   tremor   in   Parkinson   disease.  Neurology.  2020;;95(11):e1461-­e1470.  13.  Macerollo   A,   Palmer   C,   Foltynie   T,   et   al.   High-­frequency   peripheral   vibration  decreases   completion   time   on   a   number   of   motor   tasks.  Eur   J   Neurosci.  2018;;48(2):1789-­1802.  
14.  Guy   W.  ECDEU   Assessment   Manual   for   Psychopharmacology.  Rockville,   MD:  U.S.  Department  of  Health,  Education,  and  Welfare;;  1976.  15.  Ondo   W,   Hashem   V,   LeWitt   PA,   et   al.   Comparison   of   the   Fahn-­Tolosa-­Marin  Clinical  Rating  Scale  and  the  Essential  Tremor  Rating  Assessment  Scale.  Mov  Disord  Clin  Pract.  2018;;5(1):60-­65.  16.  Comella   CL,   Stebbins   GT,   Goetz   CG,   Chmura   TA,   Bressman   SB,   Lang   AE.  Teaching  tape  for  the  motor  section  of  the  Toronto  Western  Spasmodic  Torticollis  Scale.  Mov  Disord.  1997;;12(4):570-­575.    